BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 16432775)

  • 1. [Fabry disease--a provocation for pediatrics].
    Hoffmann B; Mayatepek E
    Klin Padiatr; 2006; 218(1):38-40. PubMed ID: 16432775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Anderson-Fabry disease].
    Kes P; Basić-Jukić N; Brunetta B; Jurić I
    Acta Med Croatica; 2006; 60(1):55-8. PubMed ID: 16802573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on Fabry disease: kidney involvement, renal progression and enzyme replacement therapy.
    Breunig F; Wanner C
    J Nephrol; 2008; 21(1):32-7. PubMed ID: 18264934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fabry disease: molecular genetics of the inherited nephropathy.
    Desnick RJ; Astrin KH; Bishop DF
    Adv Nephrol Necker Hosp; 1989; 18():113-27. PubMed ID: 2564247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fabry disease: treatment and diagnosis.
    Rozenfeld PA
    IUBMB Life; 2009 Nov; 61(11):1043-50. PubMed ID: 19859978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Fabry disease in Italy: first epidemiologic and collaborative study].
    Ricci R; Castorina M; Di Lillo M; Antuzzi D; Frustaci A; Parini R; Menni F; Furlan F; Burlina A; Burlina A; Catuogno S; Gabrielli O; Burattini I; Borsini W; Buchner S; Ferriozzi S; Spisni C; De Vito R; Di Rocco M; Aricò M; Pistone G; Bongiorno AM; Morrone A; Cavicchi C; Zammarchi E
    Ann Ital Med Int; 2004; 19(4):269-75. PubMed ID: 15678707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Fabry disease: clinic and enzymatic diagnosis of homozygous and heterozygous. New therapeutic prospects].
    Peces R; Olea T
    Nefrologia; 2002; 22(6):540-6. PubMed ID: 12516287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced glucosylceramide in the mouse model of Fabry disease: correction by successful enzyme replacement therapy.
    Quinta R; Rodrigues D; Assunção M; Macedo MF; Azevedo O; Cunha D; Oliveira P; Sá Miranda MC
    Gene; 2014 Feb; 536(1):97-104. PubMed ID: 24334116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fabry disease: clinical spectrum and evidence-based enzyme replacement therapy.
    Desnick RJ; Banikazemi M
    Nephrol Ther; 2006 Jan; 2 Suppl 2():S172-85. PubMed ID: 17373219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical spectrum of Anderson Fabry disease in a Romanian family.
    Tudor A; Muşat A; Doscan A; Bari M; Zapucioiu C; Urdea E; Cochior D; Peţa D
    Rom J Intern Med; 2006; 44(2):201-10. PubMed ID: 17236300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adults.
    Ortiz A; Oliveira JP; Wanner C; Brenner BM; Waldek S; Warnock DG
    Nat Clin Pract Nephrol; 2008 Jun; 4(6):327-36. PubMed ID: 18431378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fabry disease.
    Tarabuso AL
    Skinmed; 2011; 9(3):173-7. PubMed ID: 21675497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tissue and plasma globotriaosylsphingosine could be a biomarker for assessing enzyme replacement therapy for Fabry disease.
    Togawa T; Kawashima I; Kodama T; Tsukimura T; Suzuki T; Fukushige T; Kanekura T; Sakuraba H
    Biochem Biophys Res Commun; 2010 Sep; 399(4):716-20. PubMed ID: 20692233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enzyme replacement therapy for Fabry disease: morphologic and histochemical changes in the urinary sediments.
    Utsumi K; Mitsuhashi F; Asahi K; Sakurazawa M; Arii K; Komaba Y; Katsumata T; Katsura K; Kase R; Katayama Y
    Clin Chim Acta; 2005 Oct; 360(1-2):103-7. PubMed ID: 16112661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pediatric Fabry disease.
    Ries M; Gupta S; Moore DF; Sachdev V; Quirk JM; Murray GJ; Rosing DR; Robinson C; Schaefer E; Gal A; Dambrosia JM; Garman SC; Brady RO; Schiffmann R
    Pediatrics; 2005 Mar; 115(3):e344-55. PubMed ID: 15713906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ocular features of Fabry disease: diagnosis of a treatable life-threatening disorder.
    Samiy N
    Surv Ophthalmol; 2008; 53(4):416-23. PubMed ID: 18572058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An easy and sensitive method for determination of globotriaosylceramide (Gb3) from urinary sediment: utility for Fabry disease diagnosis and treatment monitoring.
    Rozenfeld PA; De Francesco NP; Borrajo GJ; Ceci R; Fossati CA
    Clin Chim Acta; 2009 May; 403(1-2):194-7. PubMed ID: 19268437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Fabry disease--diagnostic guideline].
    Constantin T; Rákóczi E; Ponyi A; Ambrus C; Kádár K; Vastagh I; Dajnoki A; Tóth B; Bokrétás G; Müller V; Katona M; Csikós M; Fiedler O; Széchey R; Varga E; Rudas G; Kertész A; Molnár S; Kárpáti S; Nagy V; Magyar P; Mahdi M; Németh K; Bereczki D; Garami M; Erdos M; Maródi L; Fekete G;
    Orv Hetil; 2010 Feb; 151(7):243-9. PubMed ID: 20133243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fabry disease in patients with end-stage renal failure: the potential benefits of screening.
    Bekri S; Enica A; Ghafari T; Plaza G; Champenois I; Choukroun G; Unwin R; Jaeger P
    Nephron Clin Pract; 2005; 101(1):c33-8. PubMed ID: 15886492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fabry disease: a review of current management strategies.
    Mehta A; Beck M; Eyskens F; Feliciani C; Kantola I; Ramaswami U; Rolfs A; Rivera A; Waldek S; Germain DP
    QJM; 2010 Sep; 103(9):641-59. PubMed ID: 20660166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.